Headquartered in Cambridge, MAP Patient Access is a leader in market access consulting services to the pharmaceutical and biotech sectors. The company is dedicated to accelerating patient access to ground-breaking medicines, devices, and diagnostics. It has a proven track record of helping its customers navigate increasingly complex healthcare reimbursement pathways, with expertise in rare and orphan diseases and cell and gene therapies.
The investment, which is Kester’s fifth in the Life Sciences sector, will be used to accelerate the growth of the MAP Platform through broadening its services, expansion into new markets and targeted acquisitions.
Increasing pressure on healthcare budgets is driving higher levels of scrutiny from healthcare advisory bodies around the world and, with its deep domain expertise, MAP is well positioned to help its customers navigate these challenges.
Adam Maidment, Managing Partner of Kester Capital, said: “Kester has been targeting the market access and reimbursement sector for some time and we are delighted to have the opportunity to invest in MAP, one of the leading businesses in this space. We are looking forward to partnering with Dan, Christian and the existing management team to continue the growth of the business organically and through acquisition.”
Dan Spacie, CEO at MAP, said: “This deal is a significant milestone for MAP, and we are excited to be partnering with the team at Kester, an investor with a long and successful track record in the Life Sciences sector. MAP has huge potential for growth, and I am looking forward to leading the organisation as we move into this next phase.”
MAP’s CSO and Co-founder Christian Hill added: “I am excited to be working with Dan and Kester to continue MAP’s journey and I am confident that their experience and expertise, supported by an exceptional management team, will unleash the potential from the amazing foundation of patient access success we have delivered over the past decade.”
Jonathan Greenwood, Partner at Mills & Reeve, who led the team advising MAP, said: “This is an exciting time for the MAP team which is in a great position to capitalise on its market leading position in a high growth sector. The investment provides an excellent platform from which to accelerate its organic growth and acquisition strategy to achieve ambitious expansion.”
Christian added: “Jonathan and his team at Mills & Reeve helped navigate us through all stages of what was a complex legal process and brought in several experts to ensure the deal was completed within the timeframe which was important as this was our first such transaction.”
Our content explained
Every piece of content we create is correct on the date it’s published but please don’t rely on it as legal advice. If you’d like to speak to us about your own legal requirements, please contact one of our expert lawyers.